Slow Capital Inc. Takes $397,000 Position in Biogen Inc (BIIB)

Slow Capital Inc. bought a new position in Biogen Inc (NASDAQ:BIIB) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 1,249 shares of the biotechnology company’s stock, valued at approximately $397,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Advisors Asset Management Inc. raised its holdings in shares of Biogen by 63.1% during the third quarter. Advisors Asset Management Inc. now owns 13,337 shares of the biotechnology company’s stock worth $4,176,000 after acquiring an additional 5,160 shares during the period. Buckingham Capital Management Inc. raised its holdings in shares of Biogen by 13.2% during the third quarter. Buckingham Capital Management Inc. now owns 2,723 shares of the biotechnology company’s stock worth $853,000 after acquiring an additional 318 shares during the period. Dynamic Technology Lab Private Ltd raised its holdings in shares of Biogen by 48.7% during the third quarter. Dynamic Technology Lab Private Ltd now owns 1,160 shares of the biotechnology company’s stock worth $363,000 after acquiring an additional 380 shares during the period. Fuller & Thaler Asset Management Inc. raised its holdings in shares of Biogen by 1.8% during the third quarter. Fuller & Thaler Asset Management Inc. now owns 19,600 shares of the biotechnology company’s stock worth $6,137,000 after acquiring an additional 350 shares during the period. Finally, Icon Advisers Inc. Co. acquired a new stake in shares of Biogen during the third quarter worth $1,785,000. Institutional investors own 88.90% of the company’s stock.

How to Become a New Pot Stock Millionaire

Biogen Inc (NASDAQ:BIIB) opened at $271.89 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.34 and a quick ratio of 2.07. The company has a market cap of $58,664.22, a PE ratio of 22.81, a PEG ratio of 1.52 and a beta of 0.90. Biogen Inc has a 12-month low of $244.28 and a 12-month high of $370.57.

Biogen (NASDAQ:BIIB) last posted its earnings results on Thursday, January 25th. The biotechnology company reported $5.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.44 by ($0.18). The company had revenue of $3.31 billion for the quarter, compared to analyst estimates of $3.08 billion. Biogen had a return on equity of 38.32% and a net margin of 20.69%. The business’s quarterly revenue was up 15.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $5.04 EPS. sell-side analysts expect that Biogen Inc will post 24.87 earnings per share for the current year.

A number of equities research analysts recently commented on the stock. Deutsche Bank restated a “buy” rating and set a $373.00 price objective on shares of Biogen in a report on Friday, January 26th. Oppenheimer raised their target price on shares of Biogen from $380.00 to $400.00 and gave the company a “buy” rating in a research report on Friday, January 26th. Jefferies Group reaffirmed a “hold” rating on shares of Biogen in a research report on Friday, January 26th. BMO Capital Markets reaffirmed a “buy” rating on shares of Biogen in a research report on Thursday, January 25th. Finally, Cowen reaffirmed a “buy” rating and issued a $408.00 target price on shares of Biogen in a research report on Friday, January 26th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and twenty-two have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $370.07.

In other news, EVP Alfred Sandrock sold 259 shares of the firm’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $290.83, for a total transaction of $75,324.97. Following the completion of the sale, the executive vice president now owns 6,553 shares in the company, valued at approximately $1,905,808.99. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Robert W. Pangia sold 5,832 shares of the firm’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $329.65, for a total transaction of $1,922,518.80. Following the sale, the director now owns 23,539 shares of the company’s stock, valued at approximately $7,759,631.35. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 8,128 shares of company stock valued at $2,601,512. 0.25% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: “Slow Capital Inc. Takes $397,000 Position in Biogen Inc (BIIB)” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3293659/slow-capital-inc-takes-397000-position-in-biogen-inc-biib.html.

Biogen Company Profile

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc (NASDAQ:BIIB).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Limelight Networks  Releases FY18 Earnings Guidance
Limelight Networks Releases FY18 Earnings Guidance
Bacanora Lithium Plc  Given Average Recommendation of “Hold” by Analysts
Bacanora Lithium Plc Given Average Recommendation of “Hold” by Analysts
Summit Therapeutics  Given Consensus Rating of “Buy” by Analysts
Summit Therapeutics Given Consensus Rating of “Buy” by Analysts
Analysts Set Iteris, Inc.  PT at $9.50
Analysts Set Iteris, Inc. PT at $9.50
Head-To-Head Contrast: CVR Energy  versus Suncor Energy
Head-To-Head Contrast: CVR Energy versus Suncor Energy
Head-To-Head Contrast: Universal Technical Institute  and The Competition
Head-To-Head Contrast: Universal Technical Institute and The Competition


© 2006-2018 Ticker Report. Google+.